COLUMBIA, S.C.—The Ritedose Corporation, LLC now offers the most complete nebulized inhalation drug portfolio in the industry with the purchase of the Arformoterol Tartrate asset from PAI Pharma of Greenville, S.C.
According to the IQVIA healthcare data network, the market size of Arformoterol Tartrate oral inhalation was about $252 million in 2021. Arformoterol Tartrate is the generic equivalent to the branded drug, Brovana.
Arformoterol Tartrate oral inhalation is used to control wheezing, shortness of breath, and chest tightness caused by chronic obstructive pulmonary disease. COPD constitutes a group of lung diseases including chronic bronchitis and emphysema.
It is in a class of medications called long-acting beta agonists. It works by relaxing and opening air passages in the lungs, making it easier to breathe.
“The purchase of this asset is a milestone for the Ritedose Corporation, which got its first FDA approval to make and distribute drugs in the year 2000,” said Jody Chastain, President and CEO. “Adding this generic drug to our portfolio gives us the opportunity to serve even more patients through their healthcare providers. All the credit goes to our employees, who work diligently to make products that their friends and family members use daily.”
Ritedose is a proven 25-year leader in the aseptic production of sterile, single-dose medication for the contract development manufacturing, generics and 503B outsourcing markets. The company has delivered more than 8 billion doses since 2012 without interruption.
About The Ritedose Corporation
Founded in 1995, The Ritedose Corporation is a pioneer in aseptic production of sterile, single-dose medications. Its primary customer base includes large pharmaceutical companies, retail pharmacies, all major wholesalers, hospital systems and others in the United States. It conducts all its drug development, manufacturing and packaging on a 33-acres campus in Columbia. With 450+ employees occupying 273,000 square feet, the campus contains a 120,000 sq. ft. manufacturing facility adjacent to a 153,000 sq. ft. packaging and distribution facility. Its annual production capacity is more than two billion units of medication.